亚太地区细胞和基因治疗制造服务市场预测至 2030 年 - 区域分析 - 按类型 [细胞治疗（自体和同种异体）和基因治疗（病毒和非病毒载体）]、适应症（癌症、骨科等）、应用（临床制造和商业制造）和最终用户 [制药和生物技术公司和合同研究组织 (CRO)]
No. of Pages: 112 | Report Code: BMIRE00029300 | Category: Life Sciences
No. of Pages: 112 | Report Code: BMIRE00029300 | Category: Life Sciences
将自动化纳入细胞和基因治疗制造服务中基因疗法的生产将降低污染风险、提高一致性并降低生产成本。 Lonza Cocoon 和 Miltenyi 的 CliniMACS Prodigy 系统是市场上可实现自动化的一些设备。这些产品旨在实现单个系统内 CAR-T 流程的大多数连续单元操作的自动化。对细胞和基因治疗的需求不断增长，使得全球范围内细胞和基因治疗产品的生产从小批量生产转向大批量生产。除了不断增加的研究活动外，细胞和基因治疗从学术和临床环境到大规模生产和商业化的发展也推动了商业制造对自动化的需求。 2020 年 7 月，Thermo Fisher Scientific Inc. 和 Lyell Nutrition 合作开发和制造工艺，为癌症患者设计有效的细胞疗法。根据这一合作伙伴关系，两家公司的目标是提高 T 细胞的能力，并支持开发符合现行良好生产规范 (cGMP) 的综合平台（系统和软件）以及试剂、耗材和仪器。因此，自动化正在成为亚太细胞和基因治疗制造服务市场的新趋势。
中国于 2003 年成为第一个批准基因疗法的国家，从那时起，细胞和基因疗法治疗方法的发展在世界范围内迅速发展，其治疗潜力也大幅上升。中国政府进行了多项监管改革，以促进细胞和基因疗法的规范发展。根据 2021 年《自然》杂志发表的一项研究，全球超过 50% 的细胞治疗试验都在中国进行。目前，中国正在进行近400个以血液学、肿瘤学和实体瘤为中心的CAR-T试验。随着复星凯特的Yescarta和JW Therapeutics的Relma-cel于2021年获得国家药品监督管理局（NMPA）批准，中国的细胞治疗正在进入一个新时代。由于成本较低和患者人数较多，多家跨国公司已迁往该地区以利用这些因素。
亚太地区细胞和基因治疗制造服务市场细分分为类型、适应症、应用、最终用户和国家。
根据类型，亚太细胞和基因治疗制造服务市场分为细胞治疗和基因治疗。 2022年，细胞治疗领域在亚太细胞和基因治疗制造服务市场中占据更大份额。细胞治疗部分进一步分为自体细胞治疗和同种异体细胞治疗。基因治疗细分市场进一步细分为病毒和非病毒载体。
根据适应症，亚太细胞和基因治疗制造服务市场细分为癌症、骨科等领域。 2022年，癌症细分市场在亚太细胞和基因治疗制造服务市场中占据最大份额。
根据应用，亚太细胞和基因治疗制造服务市场分为临床制造和商业制造制造业。 2022年，商业制造领域在亚太细胞和基因治疗制造服务市场中占据最大份额。
根据最终用户，亚太细胞和基因治疗制造服务市场分为制药和基因治疗服务市场。生物技术公司和合同研究组织 (CRO)。 2022年，制药和生物技术公司细分市场在亚太细胞和基因治疗制造服务市场中占据更大份额。
按国家/地区划分，亚太细胞和基因治疗制造服务市场细分为中国、日本、印度、澳大利亚、韩国和亚太地区其他地区。 2022年，中国在亚太细胞和基因治疗制造服务市场中占据最大份额。
Catalent Inc、Charles River Laboratories International Inc、FUJIFILM Holdings Corp、Lonza Group AG、Merck KgaA、Nikon Corp、 Takara Bio Inc、Thermo Fisher Scientific Inc 和 WuXi AppTec Co Ltd 是亚太细胞和基因治疗制造服务市场上的一些领先公司。
Strategic insights for Asia Pacific Cell and Gene Therapy Manufacturing Services involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 1,007.42 Million |
| Market Size by 2030 | US$ 3,613.18 Million |
| Global CAGR (2022 - 2030) | 17.3% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2030 |
| Segments Covered |
By 类型
|
| Regions and Countries Covered | 亚太地区
|
| Market leaders and key company profiles |
The regional scope of Asia Pacific Cell and Gene Therapy Manufacturing Services refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
1. Catalent Inc
2. Charles River Laboratories International Inc
3. FUJIFILM Holdings Corp
4. Lonza Group AG
5. Merck KgaA
6. Nikon Corp
7. Takara Bio Inc
8. Thermo Fisher Scientific Inc
9. WuXi AppTec Co Ltd
The Asia Pacific Cell and Gene Therapy Manufacturing Services Market is valued at US$ 1,007.42 Million in 2022, it is projected to reach US$ 3,613.18 Million by 2030.
As per our report Asia Pacific Cell and Gene Therapy Manufacturing Services Market, the market size is valued at US$ 1,007.42 Million in 2022, projecting it to reach US$ 3,613.18 Million by 2030. This translates to a CAGR of approximately 17.3% during the forecast period.
The Asia Pacific Cell and Gene Therapy Manufacturing Services Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Cell and Gene Therapy Manufacturing Services Market report:
The Asia Pacific Cell and Gene Therapy Manufacturing Services Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Cell and Gene Therapy Manufacturing Services Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Cell and Gene Therapy Manufacturing Services Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific Cell and Gene Therapy Manufacturing Services Market
